microdosing glp-1 peptides Microdosing GLP-1: A Next-Generation Approach

10.1523/JNEUROSCI.2619-13.2013 56

Also, the comparative effectiveness of GLP1 receptor agonists and SGLT2 inhibitors has been a growing interest, and several cohort studies with robust methodology have concluded comparable dementia risk between initiators of GLP1 receptor agonists and SGLT2 inhibitors [16, 25, 26]

doi: 10.1136/annrheumdis-2019-216655 16 SotoudehmaneshRAnvariBAkhlaghiMShahraeeniSKolahdoozanS

BPC 157 was shown to restore endothelial integrity and to actually reverse most of the oxidative damage, even during reperfusion and exaggerated reperfusion

Earlier SURMOUNT-1 data further reinforced these outcomes, with tirzepatide demonstrating weight loss of up to 22.5% of body weight over 72 weeks, the highest ever recorded for a pharmacological weight loss therapy at that time

Semaglutide is a drug with 94% homology with human GLP-1